IV. Discussion
Using a registry of Japanese patients with NVAF, we examined their eligibility for Phase III trials comparing DOACs with warfarin. Approximately 50% of our “real world” registered patients with NVAF were ineligible following the inclusion and exclusion criteria we derived from reports of Phase III trials. Further comparative analysis of outcomes strongly suggested that eligibility may affect the outcomes in our patients, with significantly higher risks of major bleeding, stroke/systemic embolism, and all-cause death in ineligible patients.